Ginmedika - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 26,358 | 70,654 | 100,765 | 172,876 | 201,444 | 231,820 | 236,526 | 242,805 |
| Profit before tax | -5,807 | 20,216 | 23,467 | 49,966 | 82,941 | 79,727 | 87,092 | 79,212 |
| Net profit | -5,807 | 19,680 | 23,018 | 47,495 | 79,141 | 76,493 | 83,662 | 75,023 |
| Equity | -7,705 | 11,975 | 34,993 | 82,488 | 161,629 | 238,122 | 321,784 | 313,307 |
| Liabilities | 0 | 17,021 | 34,109 | 20,777 | 16,566 | 12,200 | 34,566 | 70,448 |
| Non-current assets | 5,486 | 20,591 | 62,690 | 87,568 | 96,965 | 97,084 | 133,805 | 135,929 |
| Current assets | 3,903 | 12,578 | 17,718 | 23,135 | 84,050 | 152,740 | 222,100 | 247,826 |
| Total assets | 9,389 | 33,169 | 80,408 | 110,703 | 181,015 | 249,824 | 355,905 | 383,755 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 15,043 | 17,892 | 28,900 |
| Social insurance contributions | - | - | - | - | - | 15,756 | 18,875 | 21,741 |
|
Financial indicators
|
||||||||
| Revenue change y/y | - | +168.1% | +42.6% | +71.6% | +16.5% | +15.1% | +2.0% | +2.7% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | -61.8% | 59.3% | 28.6% | 42.9% | 43.7% | 30.6% | 23.5% | 19.5% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | - | 164.3% | 65.8% | 57.6% | 49.0% | 32.1% | 26.0% | 23.9% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | -22.0% | 27.9% | 22.8% | 27.5% | 39.3% | 33.0% | 35.4% | 30.9% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | -22.0% | 28.6% | 23.3% | 28.9% | 41.2% | 34.4% | 36.8% | 32.6% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | - | 1.4 | 1.0 | 0.3 | 0.1 | 0.1 | 0.1 | 0.2 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 6,590 | 11,776 | 16,794 | 24,697 | 27,161 | 28,978 | 29,566 | 30,351 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Ginmedika - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2025-07-16 | 2025-08-06 | 0.72 |
| 2022-08-23 | 2022-08-29 | 3.00 |
Ginmedika - VMI tax arrears
As of 2026-09-02, the amount of overdue STI tax debt of the company Ginmedika is: 0 €
| From | To | Overdue, € |
|---|---|---|
| 2026-06-18 | 2026-09-02 | 0.3 |
| 2026-02-21 | 2026-04-01 | 0.3 |
| 2025-06-19 | 2026-02-16 | 0.3 |
| 2025-02-20 | 2025-04-02 | 0.3 |
| 2024-06-20 | 2025-01-29 | 0.3 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Ginmedika, UAB (code 304425813) is a Private Limited Liability Company engaged in medical specialists activities. In 2025, the company generated revenue of EUR 242.8K, up 2.6% year on year and 4.7% over two years. Net profit for the year was EUR 75.0K, following EUR 83.7K in 2024 and EUR 76.5K in 2023, showing a broadly stable but slightly softer profitability trend in the latest year. The 2025 profit margin was 30.9%, compared with 35.4% in 2024 and 33.0% in 2023. Balance sheet strength remained solid: total assets reached EUR 383.8K at the end of 2025, supported by equity of EUR 313.3K and liabilities of EUR 70.4K. The equity ratio stood at 81.6%, while debt-to-equity was 0.22. Return on equity was 23.9% and return on assets 19.6%. Asset turnover was 0.63x. Revenue per employee was EUR 30.4K and profit per employee EUR 9.4K, indicating efficient earnings generation relative to scale.